Milestone Pharmaceuticals Inc. (MIST)
Automate Your Wheel Strategy on MIST
With Tiblio's Option Bot, you can configure your own wheel strategy including MIST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MIST
- Rev/Share 0.0
- Book/Share -0.0924
- PB -16.9963
- Debt/Equity -9.0784
- CurrentRatio 4.6652
- ROIC -1.0521
- MktCap 133393951.0
- FreeCF/Share -0.5114
- PFCF -3.935
- PE -3.3393
- Debt/Assets 0.8982
- DivYield 0
- ROE -1.9783
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MIST | H.C. Wainwright | -- | Buy | -- | $5 | June 5, 2025 |
| Initiation | MIST | Rodman & Renshaw | -- | Buy | -- | $9 | Aug. 22, 2024 |
News
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Despite the CRL setback and heavy dilution, we remain optimistic on etripamil's long-term market potential and Milestone's investment thesis. The recent $52.5 million equity raise was poorly timed and dilutive, but it ensures Milestone's survival even if approval is delayed. Our updated financial model reflects higher risk, dilution, and a later launch, reducing risk-adjusted fair value but still offering upside.
Read More
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Published: July 11, 2025 by: Benzinga
Sentiment: Negative
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index dipping more than 250 points on Friday.
Read More
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 31,500,000 common shares and accompanying Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 31,500,000 common shares , at a combined public offering price of $1.50 per share and …
Read More
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
Published: July 07, 2025 by: Seeking Alpha
Sentiment: Positive
I rate Milestone Pharmaceuticals Inc. a Strong Buy under $2, expecting FDA approval for Cardamyst in early 2026 after addressing recent regulatory setbacks. Cardamyst offers a unique, self-administered treatment for PSVT and AFib-RVR with no direct at-home competitors, strong efficacy, and significant pricing power. Financially, Milestone has sufficient runway into 2026, with a $75M milestone payment pending approval, though another small equity raise may be needed if they experience further delays.
Read More
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Milestone Pharmaceuticals (MIST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Stock Picks From Seeking Alpha's March 2025 New Analysts
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Neutral
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.
Read More
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois.
Read More
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston.
Read More
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) on a new Method of Use patent for etripamil nasal spray (proposed trade name CARDAMYST™), its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT).
Read More
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
MONTREAL and CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced further details on its in-person and virtual Commercial Launch Plan investor event to take place in New York on Tuesday, February 25, 2025 from 10:30 AM to 12:30 PM ET.
Read More
About Milestone Pharmaceuticals Inc. (MIST)
- IPO Date 2019-05-09
- Website https://www.milestonepharma.com
- Industry Biotechnology
- CEO Joseph G. Oliveto
- Employees 33